- Home
- SOND vs CTSO Comparison
SOND vs CTSO Comparison
Compare SOND & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOND
- CTSO
- Stock Information
- Founded
- SOND 2014
- CTSO 1997
- Country
- SOND United States
- CTSO United States
- Employees
- SOND N/A
- CTSO N/A
- Industry
- SOND Hotels/Resorts
- CTSO Medical/Dental Instruments
- Sector
- SOND Consumer Discretionary
- CTSO Health Care
- Exchange
- SOND Nasdaq
- CTSO Nasdaq
- Market Cap
- SOND 50.7M
- CTSO 51.6M
- IPO Year
- SOND N/A
- CTSO N/A
- Fundamental
- Price
- SOND $3.43
- CTSO $1.03
- Analyst Decision
- SOND
- CTSO Strong Buy
- Analyst Count
- SOND 0
- CTSO 3
- Target Price
- SOND N/A
- CTSO $4.67
- AVG Volume (30 Days)
- SOND 41.3K
- CTSO 538.8K
- Earning Date
- SOND 03-03-2025
- CTSO 03-06-2025
- Dividend Yield
- SOND N/A
- CTSO N/A
- EPS Growth
- SOND N/A
- CTSO N/A
- EPS
- SOND N/A
- CTSO N/A
- Revenue
- SOND $623,240,000.00
- CTSO $37,739,531.00
- Revenue This Year
- SOND $28.50
- CTSO $9.20
- Revenue Next Year
- SOND $17.62
- CTSO $11.64
- P/E Ratio
- SOND N/A
- CTSO N/A
- Revenue Growth
- SOND 15.39
- CTSO 1.80
- 52 Week Low
- SOND $0.88
- CTSO $0.70
- 52 Week High
- SOND $10.50
- CTSO $1.59
- Technical
- Relative Strength Index (RSI)
- SOND 51.71
- CTSO 55.82
- Support Level
- SOND $2.99
- CTSO $1.00
- Resistance Level
- SOND $3.29
- CTSO $1.14
- Average True Range (ATR)
- SOND 0.29
- CTSO 0.09
- MACD
- SOND 0.02
- CTSO 0.01
- Stochastic Oscillator
- SOND 48.39
- CTSO 64.40
About SOND Sonder Holdings Inc.
Sonder Holdings Inc is engaged in providing short and long-term accommodations to travelers in various cities across North America, Europe, and the Middle East. The Sonder units in each apartment-style building and each hotel property are selected, designed, and managed directly by the Company. The Company generates revenues by providing short-term or month-to-month accommodations to its guests. The Company also provides accommodations to travelers through boutique hotels.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.